Atea Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
12.1%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$1.99next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| C-FORWARD Phase 3 Topline Results Announcement | 31 Dec 2026 |
| Planned NDA Submission for Bemnifosbuvir/Ruzasvir FDC | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Marketable Securities Quarterly256MTarget: Sufficient to fund operations through 2027
C-BEYOND Phase 3 Trial Enrollment Annually880.0Target: Fully enrolled (>880 patients)
C-FORWARD Phase 3 Trial Enrollment Progress Quarterly1.0Target: 1.00 (Complete enrollment mid-2026)
Watch Items
- C-BEYOND Phase 3 Topline Data ReadoutTrigger: Sustained Virologic Response 12 weeks post-treatment (SVR12) comparable or superior to sofosbuvir/velpatasvirAction: Evaluate clinical efficacy and prepare for NDA submission
- C-FORWARD Phase 3 Topline Data ReadoutTrigger: Sustained Virologic Response 12 weeks post-treatment (SVR12) in global populationAction: Incorporate global data into the planned NDA submission package
- AT-587 Phase 1 Clinical Trial InitiationTrigger: First-in-human dosing of AT-587 for Hepatitis E Virus (HEV)Action: Monitor safety, tolerability, and pharmacokinetics of the lead HEV candidate
Research as of 20 Jun 2026